Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2066659 | 0.85 | AOC1 (0.34) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2066432 | 0.83 | AOC1 (0.33) | AOC1AOC3KDM4E | |
| SCHEMBL2067259 | 0.82 | AOC1 (0.39) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2067232 | 0.79 | AOC1 (0.37) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2066716 | 0.76 | AOC1 (0.33) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2066910 | 0.73 | KDM4E (0.36) | AOC1AOC3KDM4EALDH1A1HPGD | |
| SCHEMBL2067196 | 0.73 | CYP3A4 (0.36) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2067248 | 0.72 | KDM4E (0.30) | KDM4E | |
| SCHEMBL2068052 | 0.72 | AOC1 (0.39) | AOC1AOC3CYP3A4TSHRRECQL | |
| SCHEMBL2066349 | 0.72 | CA12 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | AOC1 4263/4885AOC3 4133/4885CYP3A4 1999/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | AOC1 4263/4885AOC3 4133/4885CYP3A4 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.